Longer Monopolies and Single Legal Proceedings vs Generics – the Gift of CETA to Canadian Drug Patentees
Canadian pharmaceutical patent owners can expect two substantive changes in the next year following implementation of the Canada–European Union Comprehensive Economic and Trade Agreement (“CETA”):
- certificates of supplementary patent protection (“SPC”) of up to 2 years will be available to compensate for regulatory approval delay
- an overhaul of the NOC litigation procedure is expected, with current “not-so-summary” proceedings to be replaced by one action, similar to US ANDA litigation
The recently released draft implementing legislation (“Bill C30”) provides an overview of the timing and steps for SPC, with details to follow in subordinate regulations. Procedures regarding the modified NOC litigation . . . [more]


